Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg induces greater weight loss from baseline than placebo and once-daily liraglutide 3.0 mg in patients with overweight or obesity, with or without type 2 diabetes.
Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. It is taken alongside a calorie-controlled diet and increased physical activity. The dose starts low (0.25 mg) and increases every 4 weeks to 2.4 mg to minimize side effects. It is currently the most efficacious medication for weight loss, producing double-digit percentage body weight reductions over 1-2 years, superior to placebo and once-daily liraglutide.
The phase 3 STEP clinical development program to date has demonstrated that, among patients with overweight and obesity, with and without T2D, once-weekly injectable semaglutide 2.4 mg treatment induces greater weight loss from baseline than placebo (STEP 1–6) and once-daily liraglutide 3.0 mg (STEP 8).
Why this rating
Based on multiple phase 3 randomized, double-blind, placebo- and active-controlled trials (STEP 1-8) involving over 5000 subjects.
Source
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C.W. Lau et al. · Expert Review of Clinical Pharmacology · 2022
DOI 10.1080/17512433.2022.2070473
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →